Pediatrics

GINA 2026 Ingles

GINA 2026 Españo

From now on, BiliApp is recognised as a digital health innovation application, as it is included in the Digital Solutions Catalogue of the Royal College of Paediatrics and Child Health, an academic and scientific reference institution in paediatrics in England and the United Kingdom, within its Digital Health Hub 🌐 RCPCH Digital Health Hub: https://hub.rcpch.digital/ 📲 Download BiliApp: ✅️App Store (iOS-Iphone): ✅️Google Play (Android):

🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in 🇬🇧 English, 🇪🇸Español, 🇧🇷 Português,🇫🇷 Français, 🇩🇪Deutsch, 🇮🇹Italiano, and 🇷🇺Русский. 📲 Download now: 🔹 App Store 🔹 Google Play

🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in English, Español, Português, Français, Deutsch, Italiano, and Русский. 📲 Download now: 🔹 App Store 🔹 Google Play

🚀 Asthma Control Test App ✅ Free tool to assess & monitor asthma control in adults and children 📱 Download here: 🍏 iPhone: Link 🤖 Android: Link 🌍 Available in 6 languages: 🇬🇧 English, 🇪🇸 Spanish, 🇫🇷 French, 🇮🇹 Italian, 🇧🇷 Portuguese, 🇩🇪 German

🌬️ Key Facts about the Asthma Control Test (ACT/C-ACT) — for Pediatricians 1️⃣ Population & instruments 👩‍🦰👦 ACT: ≥12 y (5 items, 4-week recall). C-ACT: 4–11 y (7 items; child + caregiver). [link](https://www.jacionline.org/article/S0091-6749%2807%2900167-4/fulltext) 2️⃣ Scores & cut-offs used in practice 📊 ACT: 5–25; >19 = well controlled, ≤19 = not well controlled. C-ACT: 0–27; ≤19 = not well controlled. [link](https://pubmed.ncbi.nlm.nih.gov/16522452/) | [link](https://pubmed.ncbi.nlm.nih.gov/17353040/) 3️⃣ Minimal Clinically Important Difference (MCID) 🔄 For ACT, a ±3-point change reflects a clinically meaningful improvement/worsening and predicts differential risk in outcomes. [link](https://www.jacionline.org/article/S0091-6749%2809%2901245-7/fulltext) 4️⃣ Validity & reliability (psychometrics + physiology) 📈 ACT shows internal consistency \~0.84–0.85 and test–retest \~0.77; correlates with specialist control ratings and FEV₁. [link](https://pubmed.ncbi.nlm.nih.gov/16522452/) | [link](https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/act.php) 5️⃣ Prognostic value (risk of exacerbations) 🔮 Lower ACT scores associate with higher SABA use/exacerbation risk; maintaining ACT ≥ 20 reduces exacerbation risk. [link](https://www.sciencedirect.com/science/article/pii/S0954611119300460) | [link](https://pubmed.ncbi.nlm.nih.gov/19767070/) | [link](https://pmc.ncbi.nlm.nih.gov/articles/PMC7118934/) 6️⃣ How to apply (guideline context) 🩺 Use ACT/C-ACT with symptom history, prior exacerbations, and objective measures (e.g., spirometry) to guide step-wise therapy per GINA 2024. [link](https://ginasthma.org/wp-content/uploads/2024/12/GINA-Summary-Guide-2024-WEB-WMS.pdf)